Shilpa Medicare announced that the US FDA intimated the Company that based on its inspection from 11 November to 30 November 2017, the Unit of the Company located at S-20 TO S-24/A, Pharmaceutical Formulations SEZ TSIIC, Green Industrial Park, Polepally, Jadcherla, Mahabubnagar, Telangana, India, has been determined that the inspection classification of this facility is VAI.
The is a confirmation that earlier status of our formulation Unit is maintained.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
